Diagnostic Challenges
Diagnosis of hemorrhagic immune-mediated coagulopathy (IMC) in the postoperative setting can be challenging. The clinical presentation is variable, ranging from asymptomatic laboratory abnormalities to significant hemorrhage. The vast majority of cases have been recognized due to bleeding or significant changes in laboratory studies. The diagnosis of IMC, however, may be masked by other disease conditions.
Additionally, because of a low level of clinical awareness, the clinician may not suspect an immune-mediated basis for the coagulopathy.
This is further complicated by the time lag between antigen exposure and clinical presentation. An extensive review of published case reports of IMCs associated with the use of bovine thrombin noted that the most common time to presentation was 8 days and the median time was 11 days. The mean time to clinical presentation, however, was 32 days following surgical procedures where bovine thrombin was utilized.
Primary immune response to antigen exposure manifests about 7 - 14 days following exposure, depending on the potency of the immunogen and the sensitivity of the detection methods used. Subsequent exposure results in a secondary or anamnestic immune response characterized by a shorter lag time and more rapid rise in antibody titers along with a higher and longer steady-state antibody titer than that seen in the primary response (see figure above). Not all patients exposed to antigens will develop clinical symptoms.
Certain patterns emerge when looking at immune-mediated coagulopathies. The model below is adapted from the HIT literature and can be applied to other immune-mediated diseases. In a patient population exposed to an antigen, only a subset of patients will develop antibodies. The percentage of patients developing antibodies will vary depending on the antigen and the specific patient population. Even fewer patients will develop pathogenic antibodies, and fewer still will develop lab abnormalities and/or overt clinical manifestations.
Clinical Manifestations of Hemorrhagic IMC
The clinical manifestations of hemorrhagic IMC can vary dramatically. In its most benign form, IMC results in abnormalities in laboratory coagulation parameters without any discrete bleeding events.
When bleeding events do occur, they can range from minor events—such as epistaxis or hematuria—to major and even life-threatening bleeding events.
IMCs can consume significant medical resources, due to increased length of hospital stay, blood product utilization, and the need for therapeutic interventions such as IVIG.
References:
Ness P, Creer M, Rodgers GM, et al; the Recognition, Evaluation and Treatment of Acquired Coagulopathy Consensus (RETACC) Panel. Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety. Patient Saf Surg. 2009;3(1):8.
Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular. 2008;16(suppl 1):S29-S36.
Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607-2616.
Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205(2):256–265.
Chapel H, Haeney M, Misbah S, Snowden N. Basic components: structure and function. In: Chapel H, Haeney M, Misbah S, Snowden N, eds. Essentials of Clinical Immunology. 5th ed. Malden, MA: Blackwell Publishing, Inc.; 2006:25.
Kapoor A, Cortese Hassett AL, Bontempo FA. Lack of response bleeding from acquired factor V inhibitor to recombinant human factor VIIa concentrate. Blood. 2005;106:Abstract 4099.
Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application. Am J Med. 2005;118(7):805.
Lollar P. Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor. J Thromb Haemost. 2005;3(7):1385-1391.
Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg. 2004;18(3):349-351.
Boshkov LK, Thomas G, Reller M, Roberts C, Shen I. Bleeding due to acquired antibody factor V followed by stroke associated with high titer anticardiolipin (ACLA) antibody in a 14 month old congenital cardiac patient exposed to topical bovine thrombin. Blood. 2002;100(11):Abstract 3902.
Parslow TG. The immune response. In: Parslow TG, Stites DP, Terr AI, Imboden JB, eds. Medical Immunology. 10th ed. New York, NY: McGraw-Hill; 2001:69.
Virella G. Humoral immune response and its induction by active immunization. In: Virella G, ed. Medical Immunology. 5th ed. New York, NY: Marcel Dekker, Inc; 2001:227.
Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg. 2000;15(6):378-382.
Muntean W, Zenz W, Finding K, Zobel G, Beitzke A. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr. 1994;83(1):84-87.